[go: up one dir, main page]

EA202092125A1 - Антитела против рецептора фолата 1 и их применения - Google Patents

Антитела против рецептора фолата 1 и их применения

Info

Publication number
EA202092125A1
EA202092125A1 EA202092125A EA202092125A EA202092125A1 EA 202092125 A1 EA202092125 A1 EA 202092125A1 EA 202092125 A EA202092125 A EA 202092125A EA 202092125 A EA202092125 A EA 202092125A EA 202092125 A1 EA202092125 A1 EA 202092125A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
receptor
antibodies against
application
against folate
Prior art date
Application number
EA202092125A
Other languages
English (en)
Inventor
Минхань Ван
Хой Цзоу
Хайцюнь Цзя
Original Assignee
Фейнз Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фейнз Терапьютикс, Инк. filed Critical Фейнз Терапьютикс, Инк.
Publication of EA202092125A1 publication Critical patent/EA202092125A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны антитела против FOLR1 и их антигенсвязывающие фрагменты. Описаны также нуклеиновые кислоты, кодирующие антитела, композиции, содержащие антитела, способы получения антител и способы применения антител для лечения или предотвращения заболеваний, таких как злокачественная опухоль.
EA202092125A 2018-03-13 2019-03-07 Антитела против рецептора фолата 1 и их применения EA202092125A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862642213P 2018-03-13 2018-03-13
PCT/US2019/021084 WO2019177854A1 (en) 2018-03-13 2019-03-07 Anti-folate receptor 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202092125A1 true EA202092125A1 (ru) 2020-12-15

Family

ID=67906883

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092125A EA202092125A1 (ru) 2018-03-13 2019-03-07 Антитела против рецептора фолата 1 и их применения

Country Status (13)

Country Link
US (1) US11873335B2 (ru)
EP (1) EP3765521A4 (ru)
JP (2) JP7433236B2 (ru)
KR (1) KR20200132900A (ru)
CN (2) CN115925952A (ru)
AU (1) AU2019236091A1 (ru)
BR (1) BR112020016469A2 (ru)
CA (1) CA3091683A1 (ru)
EA (1) EA202092125A1 (ru)
IL (1) IL276949A (ru)
MX (1) MX2020009522A (ru)
SG (1) SG11202007494TA (ru)
WO (1) WO2019177854A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102275930B1 (ko) 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
EP4077377A4 (en) * 2019-12-17 2024-07-03 Phanes Therapeutics, Inc. BISPECIFIC ANTIBODIES WITH ALTERNATING INTERCHAIN CYSTEINES AND USES THEREOF
TW202233684A (zh) * 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CN115491358B (zh) * 2021-06-17 2024-09-06 复星凯特生物科技有限公司 一种靶向b7-h3和folr1双打靶点car t的制备及应用
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214331B2 (en) * 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
FR2929946B1 (fr) 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
JP5778700B2 (ja) * 2010-02-24 2015-09-16 イミュノジェン， インコーポレイテッド フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
KR20140032944A (ko) 2010-10-20 2014-03-17 모르포테크, 인크. 항폴레이트 수용체 알파 항체 당형태
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
WO2012099973A2 (en) 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US9512223B2 (en) 2012-05-15 2016-12-06 Morphotek, Inc. Methods for treatment of gastric cancer
MX362514B (es) * 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP6224619B2 (ja) 2012-12-07 2017-11-01 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
JP6233933B2 (ja) 2012-12-25 2017-11-22 国立大学法人 鹿児島大学 葉酸リセプターα及びβを認識する抗体
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2997044A4 (en) 2013-05-14 2017-03-22 ImmunoGen, Inc. Anti-folr1 immunoconjugate dosing regimens
BR112015031950A2 (pt) 2013-06-20 2017-07-25 Morphotek Inc métodos para tratamento de câncer de ovário
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
HUE067367T2 (hu) 2013-10-08 2024-10-28 Immunogen Inc ANTI-FOLR1 immunkonjugátum adagolási rendszer
EP3077522A1 (en) 2013-12-04 2016-10-12 Immunogen, Inc. Compositions and methods for antibody production
MX2016016490A (es) 2014-06-20 2017-07-28 Bioalliance Cv Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos.
SG10201901825YA (en) 2014-09-03 2019-03-28 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
EP3221356B1 (en) * 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
RU2753902C2 (ru) * 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2983126A1 (en) 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
CA2994888A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
EP3526254A1 (en) 2016-10-12 2019-08-21 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
EP3544999A1 (en) 2016-11-23 2019-10-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
JP2020519675A (ja) 2017-05-16 2020-07-02 イミュノジェン・インコーポレーテッド 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ−１抗体の組み合わせ

Also Published As

Publication number Publication date
EP3765521A4 (en) 2022-03-23
BR112020016469A2 (pt) 2020-12-15
CN111954681B (zh) 2022-12-06
JP2021517459A (ja) 2021-07-26
CN111954681A (zh) 2020-11-17
WO2019177854A1 (en) 2019-09-19
MX2020009522A (es) 2020-10-22
US20210002363A1 (en) 2021-01-07
SG11202007494TA (en) 2020-09-29
EP3765521A1 (en) 2021-01-20
JP2024056787A (ja) 2024-04-23
CA3091683A1 (en) 2019-09-19
KR20200132900A (ko) 2020-11-25
AU2019236091A1 (en) 2020-09-03
JP7433236B2 (ja) 2024-02-19
IL276949A (en) 2020-10-29
CN115925952A (zh) 2023-04-07
US11873335B2 (en) 2024-01-16

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
NZ766968A (en) Anti-cd73 antibodies and uses thereof
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA202091747A1 (ru) Составы антитела b7-h4
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
EA201791590A1 (ru) Антитела к tau и их применение
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
MY200162A (en) Anti-gitr antibodies and uses thereof
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202190807A1 (ru) Антитела к синуклеину
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
EA202092518A1 (ru) Композиции и способы лечения рака
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
ZA202110285B (en) Antibodies and methods of use
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения